Strategies to optimize HIV treatment outcomes in resource-limited settings
- PMID: 19940945
Strategies to optimize HIV treatment outcomes in resource-limited settings
Abstract
Although the availability of antiretroviral therapy has increased rapidly to reach over three million people in low- and middle-income countries, coverage remains low as only 31% of people in need were receiving antiretroviral therapy in sub-Saharan Africa. Antiretroviral therapy scale-up needs to continue to grow exponentially to meet the need for universal access and keep pace with or exceed the new HIV infections. This calls for strategies that will have the greatest impact on the reduction of opportunistic infections, toxicities, and early mortality after antiretroviral therapy initiation as well improve adherence, clinical, immunological, and virologic responses, patient retention in antiretroviral therapy programs, and overall quality of life of people living with HIV/AIDS. Expanding antiretroviral therapy to all those eligible requires evidence-based decisions about how, when, and where expansion should occur. In this article we highlight some of the strategies that have optimized HIV treatment outcomes within the constraints of limited resources in sub-Saharan Africa. Key strategies to optimize HIV treatment outcomes include, i) scaling up HIV testing to identify all in need of HIV treatment, ii) strengthening the links between HIV diagnosis and comprehensive HIV/AIDS care, iii) timely initiation of antiretroviral therapy, iv) optimal diagnosis and treatment of opportunistic infections and comorbidities, v) investing in laboratory tests to support clinical monitoring of patients on antiretroviral therapy, vi) maximizing adherence to antiretroviral medication and retention of patients in HIV/AIDS care, viii) improving the health infrastructure, and increasing the human resources to handle the growing numbers of people in need of HIV treatment.
Similar articles
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Early initiation of antiretroviral therapy and universal HIV testing in sub-Saharan Africa: has WHO offered a milestone for HIV prevention?J Public Health Policy. 2010 Dec;31(4):385-400. doi: 10.1057/jphp.2010.29. J Public Health Policy. 2010. PMID: 21119646
-
A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Antiviral Res. 2008. PMID: 18571246 Review.
-
Inequalities in health: access to treatment for HIV/AIDS.Ann Ist Super Sanita. 2007;43(4):313-6. Ann Ist Super Sanita. 2007. PMID: 18209264 Review.
-
Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda.Clin Infect Dis. 2003 Jul 1;37(Suppl 1):S13-24. doi: 10.1086/375368. Clin Infect Dis. 2003. PMID: 12822128
Cited by
-
Impaired T-cell proliferation among HAART-treated adults with suboptimal CD4 recovery in an African cohort.BMC Immunol. 2013 Jun 20;14:26. doi: 10.1186/1471-2172-14-26. BMC Immunol. 2013. PMID: 23786370 Free PMC article.
-
Delayed Antiretroviral Therapy (ART) Initiation among Hospitalized Adults in a Resource-Limited Settings: A Challenge to the Global Target of ART for 90% of HIV-Infected Individuals.AIDS Res Treat. 2019 Apr 1;2019:1832152. doi: 10.1155/2019/1832152. eCollection 2019. AIDS Res Treat. 2019. PMID: 31057959 Free PMC article.
-
Lack of Effectiveness of Antiretroviral Therapy in Preventing HIV Infection in Serodiscordant Couples in Uganda: An Observational Study.PLoS One. 2015 Jul 14;10(7):e0132182. doi: 10.1371/journal.pone.0132182. eCollection 2015. PLoS One. 2015. PMID: 26171777 Free PMC article.
-
High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort.BMC Immunol. 2014 Jan 31;15:2. doi: 10.1186/1471-2172-15-2. BMC Immunol. 2014. PMID: 24483185 Free PMC article.
-
Re-emerging Aspartic Protease Targets: Examining Cryptococcus neoformans Major Aspartyl Peptidase 1 as a Target for Antifungal Drug Discovery.J Med Chem. 2021 May 27;64(10):6706-6719. doi: 10.1021/acs.jmedchem.0c02177. Epub 2021 May 18. J Med Chem. 2021. PMID: 34006103 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical